Gastroesophageal reflux and Helicobacter pylori: A review

World Journal of Gastroenterology

Volumn 6, Issue 3, 2000, Pages 311-314

  Pace, F ^a,b   Bianchi Porro, G ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR;

BACTERIAL INFECTION; DEVELOPED COUNTRY; DRUG INHIBITION; GASTRITIS; GASTROESOPHAGEAL REFLUX; HELICOBACTER PYLORI; HUMAN; NONHUMAN; PEPTIC ULCER; REVIEW; STOMACH TUMOR;

EID: 0034081984     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v6.i3.311     Document Type: Review

References (37)

1. Labenz J, Blum AL, Bayerdorffer E, Meining A, Stolte M, Borsh G. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology , 1997;112:1442-1447
2. Howard PJ, Heading RC. Epidemiology of gastro-oesophageal reflux disease. World J Surg , 1992;16:288-293
3. Pera M, Cameron AJ, Trastek VF, Carpenter HA, Zinsmeister AR. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Castroenterology , 1993;104;910-913
4. El-Serag HB, Sonnenberg A. Opposite time trends of peptic ulcer and reflux disease. Gut , 1998;43:327-333
5. Marshall BJ. Epidemiology of H. pylori in western countries. in: Hunt RH, Tytgat GN. Helicobacter pylori. Basic mechanism to clinical cure. Dordrecht: Kluwer Acad Pub , 1994:75-84
6. Xia HH, Talley NJ. Helicobacter pylori infection, reflux esophagitis and atrophic gastritis: an unexplored triangle. Am J Gastroenterol , 1998;93:394-400
7. Richter JE, Falk GW, Vaezi MF. Helicobacter pylori and gastroesophageal reflux disease: the bug may not be all bad. Am J Gastroenterol , 1998;93:1800-1802
8. Pace F, Bianchi Porro G. Gastro-oesophageal reflux and Helicobacter pylori. Ital J Gastroenterol Hepatol , 1998;30(Suppl 3):289-293
9. OConnor HJ. Helicobacter pylori and gastro-oesophageal reflux disease clinical implications and management. Aliment Pharmacol Ther , 1999;13:117-127
10. El-Serag BH, Sonnenberg A, Jamal MM, Inadomi JM, Crooks LA, Feddersen RM. Corpus gastritis is protective against reflux oesophagitis. Gut , 1999;45:181-185
11. Dodds WJ, Dent J, Hogan WJ, Helm JF, Hauser R, Patel GK, Egide MS. Mechanism of gastroesophageal reflux in patients with reflux esophagitis. N Engl J Med , 1982;307:1547-1552
12. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology , 1997;112:1798-1810
13. Verdu EF, Armstrong D, Fraser R, Viani F, Idstrom J, Cederberg C, Blum AL. Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut , 1995;36:539 -543
14. Verdu EF, Armstrong D, Idstrom JP, Labenz J, Stolte M, Dorta G, Borsch G, Blum AL. Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole. Gut , 1995;37:743-748
15. Labenz J, Tillenburg B, Peitz U, Idstrom JP, Verdù E, Stolte M, Blum AL. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology , 1996; 110:725-732
16. Labenz J, Tillenburg B, Peitz U, Idstrom JP, Verdù E, Stolte M, Bosch G, Blum AL. Efficacy of omeprazole one year after cure of Helicobacter pylori infection in duodenal ulcer patients. Am J Gastroenterol , 1997;92:576-578
17. Van Herwaarden MA, Samson M, Van Nispen CHM, Mulder PGH, Smout AJP. The effect of Helicobacter pylori eradication on intragastric pH during dosing with lansoprazole or ranitidine. Aliment Pharmacol Ther , 1999;13:731-740
18. Peters FT, Kuipers EJ, Ganesh S, Sluiter WJ, Klinkenberg-Knol EC, Lamers CB, Kleibeuker JH. The influence of Helicobacter pylori on esophageal acid exposure in GERD during acid suppressive therapy. Aliment Pharmacol Ther , 1999;13:921-926
19. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, Eskes SA, Meuwissen SGM. Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease. Am J Gastroenterol , 1999;94:884-887
20. Hatlebakk JG, Berstad A. Prognostic factors for relapse of reflux oesophagitis and symptoms during 12 months of therapy with omeprazole. Aliment Pharmacol Ther , 1997;11:1093-1099
21. Holtmann G, Cain C, Malfertheiner P. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology , 1999;117: 11-16
22. Howden CW, Hunt RH. Guidelines for the management of Helicobacter pylori infection. Am J Gastroenterol , 1998;93:2330-2338
23. Kuipers EJ, Uyterlinde AM, Pena AS, Hazenberg HJA, Bloemena E, Lindeman J, Klinkberg-Knol E, Meuwissen SGNM. Increase of Helicobacter pylori -associated corpus gastritis during acid-suppressive therapy: implications for long-term safety. Am J Gastroenterol , 1995; 90:1401-1406
24. Logan RPH, Walker MM, Misiewicz JJ, Gummett PA, Karim QN, Baron JH. Changes in intragastric distribution of Helicobacter pylori during treatment with omeprazole. Gut , 1995;36;12-16
25. Eissele R, Brunner G, Simon B, Solcia E, Arnold R. Gastric mucosa during treatment with lansoprazole; Helicobacter pylori is a risk factor for argyrophil-cell hyperplasia. Gastroenterology , 1997; 112; 707-715
26. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, Havu N, Festen HPM, Liedman B, Lamers CBHW, Jansen JBMJ, Dalenback J, Snel P, Nelis GF, Meuwissen SGNM. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Eng J Med , 1996;334:1018-1022
27. Genta RM. Acid suppression and gastric atrophy: sifting fact from fiction. Gut ,1998;43(Suppl 1):35-38
28. Lundell L, Miettinen P, Myrvold HE, Pedersen SA, Thor K, Andersson A, Hattlebakk J, Janatuinen E, Lecander C, Liedman B, Nystrom P, and the NORDIC GERD STUDY GROUP. Lack of effect of acid suppression therapy on gastric atrophy. Gastroenterology , 1999;117:319-326
29. Labenz J. Does Helicobacter pylori affect the management of gastroesophageal reflux disease? ( Editorial ). Am J Gastroenterol , 1999;94:867-869
30. Barrett NR. Chronic peptic ulcer of the oesophagus and "oesophagitis". Br J Surg , 1950; 38:175-182
31. Hameeteman W. Barrett's esophagus and adenocarcinoma. In: Bianchi Porro G, Pace F, eds. Argomenti di patologia esofagea, Vol. 3. Milano: Springer Verlag Italia , 1998:5-27
32. Loffeld RJLF, Ten Tije BJ, Arends JW. Prevalence and significance of Helicobacter pylori in patients with Barrett's esophagus. Am J Gastroenterol , 1992;87:1598-1600
33. Sharma VK, Demian SE, Taillon D, Vasuveda R, Howden CW. Examination of tissue distribution of Helicobacter pylori within columnar-lined esophagus. Dig Dis Sci , 1999;44:1165-1168
34. Hackelsberger A, Guenther T, Schultze V, Labenz J, Roessner A, Malfertheiner P. Prevalence and pattern of Helicobacter pylori gastritis in the gastric cardia .Am J Gastroenterol , 1997;92:2220-2224
35. Goldblum JR, Vicari JJ, Falk GW, Rice TW, Peek RM, Easley K, Richter JE. Inflammation and intestinal metaplasia of the gastric cardia: the role of gastroesophageal reflux and H. pylori infection. Gastroenterology , 1998;114:633-639
36. Quddus MR, Henley JD, Sulaiman RA, Palumbo TC, Gnepp DR. Helicobacter infection and adenocarcinoma arising in Barrett's esophagus. Hum Pathol , 1997;28:1007-1009
37. Wright TA, Myskow M, Kingsnorth AN. Helicobacter pylori colonization of Barrett's esophagus and its progression to cancer. Dis Esophagus , 1997;10:196-200